1) Philip R. Dodge Young Investigator Award: An award for basic science or clinical research by promising young investigators who are members of the Child Neurology Society. Applications will be judged on the basis of originality, scientific merit, succinctness, and relevance. The recipient of the Dodge award will receive a grant-in-aid of $20,000 and will be invited to present their work at the 46th Annual Meeting of the Child Neurology Society in Kansas City, MO on October 6, 2017.
2) Child Neurology Shields Research Grant: The grant supports translational or clinical research by a child neurologist or developmental pediatrician early in his/her academic career. The selected investigator will receive a $100,000 grant of $50,000 per year for two years.
3) Pediatric Epilepsy Research Foundation (PERF) Scientific Research Grant: The grant supports clinical or basic science research by a child neurologist or developmental pediatrician early in his/her academic career. The selected investigator will receive a $100,000 grant of $50,000 per year for two years.
This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of clinical studies that address critical needs for clinical trial readiness in rare neurological and neuromuscular diseases. These studies should result in clinically validated biomarkers and clinical outcome assessment measures appropriate for use in upcoming clinical trials. Through the support of trial readiness studies, NINDS and NCATS expect to enhance the quality and increase the likelihood of success of clinical trials in these rare diseases.
The National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA) intend to publish a Funding Opportunity Announcement (FOA) to solicit applications for a large prospective clinical research study to determine the specific subsets of stroke events that predict cognitive impairment and dementia in post-stroke populations in the United States, including in health disparities populations, and what additional clinical factors and comorbidities along the AD/ADRD spectrum may causally synergize with stroke to result in (or prevent) cognitive impairment and dementia outcomes. The goals of this initiative are to determine the association between specific subsets of stroke events and subsequent cognitive impairment and dementia in post-stroke populations in the United States, including in health disparities populations; to identify additional clinical factors and comorbidities that may affect these associations; and to contribute to development and validation of clinical-trial ready diagnostic and progression biomarkers for post-stroke dementia. It is expected that the study design will also allow for determination of interrelationships (cross-sectional and longitudinal) among the stroke event, overall cerebrovascular and cardiovascular disease and risk factors (including sex, racial, and ethnic differences), dementia-relevant genetic variants (including ApoE) and mutations (e.g. in Notch 3) previously associated with Alzheimer's disease (e.g. APP, PS1, PS2, PICALM, CLU, TREM2), cognitive trajectories including decline and resistance to decline, as well as amyloid and tau biomarkers of Alzheimers pathology during life.
This Funding Opportunity Announcement (FOA) invites innovative research grant applications focused on identifying potential mechanisms and risk factors underlying HIV treatment associated neuropsychiatric symptoms and neurological toxicities experienced by some people living with HIV infection. Exploratory and high-risk research projects that may lead to identification of targets for therapeutic interventions or personalized medicine are appropriate for this FOA. Basic and preclinical research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required.
The goal of this FOA is to support research that will lead to a greater understanding of complex mechanisms by which the brain glymphatic system and meningeal and peripheral lymphatic systems change in normal and pathological brains. This knowledge is critical to determine whether a functional impairment or disruption of these systems may be involved in neurological disorders that are associated with immune system dysfunction, such as Alzheimer's disease.
The FOA encourages the submission of research project applications to determine nicotine's modulatory effects on peripheral and central immune system functions in the presence of HIV-1 infection. Specifically, NIDA is particularly interested in projects exploring the ability of nicotine to produce anti-inflammatory and protective effects, and the translational potential of the new knowledge in attenuating HIV-induced pathologies and HIV-associated CNS complications such as neurological/cognitive disorders.
The purpose of this funding opportunity announcement (FOA) is to support mechanistic clinical studies aimed at understanding the impact of arts-based approaches in palliative care for symptom management. This FOA is intended to support mechanistic clinical studies to provide an evidence base for the use of the arts in palliative care for symptom management. The objective is to understand the biological, physiological, neurological, psychological, and/or sociological mechanisms by which the arts exert their effects on symptom management during and throughout the palliative care continuum. The goal is for the research supported under this FOA to develop an evidence-base that could be used as a basis for the uptake of arts-based therapies in palliative care settings, among individuals across the lifespan, with a wide variety of serious chronic conditions and their accompanying symptoms. This FOA is not intended to determine efficacy or the comparative effectiveness of interventions, or to assess interventions designed to treat the underlying cause of a particular disease state.
This Funding Opportunity Announcement (FOA) invites research grant applications to study the cellular and molecular mechanisms delineating the neuropathophysiology of HIV-associated neurological disorders (HAND) in the setting of long-term combination antiretroviral therapy (cART) conditions using induced microglia and cerebral organoids generated from patient derived induced pluripotent stem cell (iPSC) lines.
The purpose of the U.S.-China Program for Biomedical Collaborative Research is to stimulate collaborative basic, translational, and clinical research between United States (U.S.)-based researchers and Chinese researchers in the areas of cancer, environmental health, heart disease, blood disorders, diseases of the eye and visual system, mental health, and neurological disorders. Partnering U.S. and Chinese investigators must work jointly to submit identical applications to NIH and National Natural Science Foundation of China (NSFC), respectively. U.S. investigators must respond to the announcement from NIH, including the Chinese application as an attachment, and Chinese investigators must respond to a separate funding announcement from NSFC, including the NIH application as an attachment.
This FOA provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological disorders that fall under the NINDS mission. Therapeutic agents may include but are not limited to small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the NINDS Cooperative Research to Enable and Advance Translational Enterprises for Biologics program (CREATE Bio) program for biologics, biotechnology products, Blueprint Neurotherapeutics Network for small molecules, or other translational programs.
This Funding Opportunity Announcement (FOA) invites grant applications for research to examine the safety and efficacy of the inclusion of animals in therapy and rehabilitation for children and individuals with disabilities, neurological conditions, behavioral, emotional and mental health issues and related health outcomes, as well as the adaptation of healthy behaviors and the enhancement of learning in special need and at-risk populations.
This Funding Opportunity Announcement (FOA) is issued by the National Institute of Neurological Disorders and Stroke (NINDS) in conjunction with the NIH Pain Consortium. It solicits R21 grant applications from institutions/organizations to perform innovative research that will elucidate the mechanisms underlying migraine, expand our current knowledge of the role of genetic, physiological, biopsychosocial, and environmental influences in migraine susceptibility and progression, and explore new therapeutic targets and therapies for acute migraine management and longer term prevention.
The purpose of this Funding Opportunity Announcement (FOA) is to support rigorous analytical validation of candidate biomarker measures or endpoints in a manner that is consistent with FDA guidelines. Analytical validation establishes that the performance characteristics of the biomarker measurement or endpoint are acceptable for its intended use. This FOA assumes that
1) a candidate biomarker has already been identified,
2) assay technology has already been developed, and
3) a working hypothesis regarding context of use is in place
Group items tagged 
